129 related articles for article (PubMed ID: 2722242)
1. Enhancement of immunoglobulin G responses in mice against hepatitis B virus surface antigen, influenza virus hemagglutinin vaccine, and tetanus toxoid by 6-O-acylated muramyl dipeptides.
Furuya T; Kumazawa Y; Takimoto H; Nagumo T; Watanabe M; Aizawa C; Kiso M; Hasegawa A; Nomoto K
Infect Immun; 1989 Jun; 57(6):1839-44. PubMed ID: 2722242
[TBL] [Abstract][Full Text] [Related]
2. Immunostimulatory activity of 1-O-acylated muramyl dipeptides, with or without a 6-O-phosphoryl group, in aqueous form.
Furuya T; Kumazawa Y; Takimoto H; Nagumo T; Nagamine T; Aizawa C; Mizunoe K; Kiso M; Hasegawa A; Nomoto K
Int J Immunopharmacol; 1989; 11(1):35-43. PubMed ID: 2496044
[TBL] [Abstract][Full Text] [Related]
3. Effect of methyl esterification of isoglutamine residue in 6-O-acylated muramyl dipeptides on expression of immunopharmacological activities.
Furuya T; Kumazawa Y; Takimoto H; Nagumo T; Kiso M; Hasegawa A; Nomoto K
Int J Immunopharmacol; 1991; 13(5):573-7. PubMed ID: 1783471
[TBL] [Abstract][Full Text] [Related]
4. Effects of muramyl dipeptide derivatives as adjuvants on the induction of antibody response to recombinant hepatitis B surface antigen.
Tamura M; Yoo YC; Yoshimatsu K; Yoshida R; Oka T; Ohkuma K; Arikawa J; Azuma I
Vaccine; 1995 Jan; 13(1):77-82. PubMed ID: 7762283
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of humoral immune responses against viral vaccines by a non-pyrogenic 6-O-acylmuramyldipeptide and synthetic low toxicity analogues of lipid A.
Tsujimoto M; Kotani S; Okunaga T; Kubo T; Takada H; Kubo T; Shiba T; Kusumoto S; Takahashi T; Goto Y
Vaccine; 1989 Feb; 7(1):39-48. PubMed ID: 2718605
[TBL] [Abstract][Full Text] [Related]
6. Active synthesis of hemagglutinin-specific immunoglobulin A by lung cells of mice that were immunized intragastrically with inactivated influenza virus vaccine.
Chen KS; Burlington DB; Quinnan GV
J Virol; 1987 Jul; 61(7):2150-4. PubMed ID: 3586130
[TBL] [Abstract][Full Text] [Related]
7. Production of antibodies recognizing a hepatitis B virus (HBV) surface antigen by administration of murabutide associated to a synthetic pre-S HBV peptide conjugated to a toxoid carrier.
Przewlocki G; Audibert F; Jolivet M; Chedid L; Kent SB; Neurath AR
Biochem Biophys Res Commun; 1986 Oct; 140(2):557-64. PubMed ID: 3778467
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant activity of muramyl dipeptide derivatives to enhance immunogenicity of a hantavirus-inactivated vaccine.
Yoo YC; Yoshimatsu K; Koike Y; Hatsuse R; Yamanishi K; Tanishita O; Arikawa J; Azuma I
Vaccine; 1998; 16(2-3):216-24. PubMed ID: 9607033
[TBL] [Abstract][Full Text] [Related]
9. Enhancing activity of mycobacterial cell-derived adjuvants on immunogenicity of recombinant human hepatitis B virus vaccine.
Koike Y; Yoo YC; Mitobe M; Oka T; Okuma K; Tono-oka S; Azuma I
Vaccine; 1998 Dec; 16(20):1982-9. PubMed ID: 9796054
[TBL] [Abstract][Full Text] [Related]
10. [Enhancement of the activity of hepatitis B virus vaccine by association with murabutide].
Audibert F; Przewlocki G; Lefrancier P; Choay J; Chedid L
C R Seances Acad Sci III; 1982 Nov; 295(10):611-4. PubMed ID: 6218866
[TBL] [Abstract][Full Text] [Related]
11. Phase 1 clinical tests of influenza MDP-virosome vaccine (KD-5382).
Kaji M; Kaji Y; Kaji M; Ohkuma K; Honda T; Oka T; Sakoh M; Nakamura S; Kurachi K; Sentoku M
Vaccine; 1992; 10(10):663-7. PubMed ID: 1523876
[TBL] [Abstract][Full Text] [Related]
12. Primary immune response to liposomal tetanus toxoid in mice: the effect of mediators.
Davis D; Gregoriadis G
Immunology; 1989 Oct; 68(2):277-82. PubMed ID: 2509329
[TBL] [Abstract][Full Text] [Related]
13. A novel immunostimulator, N-[alpha-O-benzyl-N-(acetylmuramyl)-L-alanyl-D-isoglutaminyl]-N6-trans-(m-nitrocinnamoyl)-L-lysine, and its adjuvancy on the hepatitis B surface antigen.
Yang HZ; Xu S; Liao XY; Zhang SD; Liang ZL; Liu BH; Bai JY; Jiang C; Ding J; Cheng GF; Liu G
J Med Chem; 2005 Aug; 48(16):5112-22. PubMed ID: 16078831
[TBL] [Abstract][Full Text] [Related]
14. Characteristics of cytotoxic T lymphocytes directed to influenza virus haemagglutinin elicited by immunization with muramyldipeptide-influenza liposome vaccine.
Iinuma H; Nerome K; Yoshioka Y; Okinaga K
Scand J Immunol; 1995 Jan; 41(1):1-10. PubMed ID: 7824883
[TBL] [Abstract][Full Text] [Related]
15. Modulation of carrier-induced epitopic suppression by Bordetella pertussis components and muramyl peptide.
Vogel FR; Leclerc C; Schutze MP; Jolivet M; Audibert F; Klein TW; Chedid L
Cell Immunol; 1987 Jun; 107(1):40-51. PubMed ID: 2438053
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and immunoadjuvant activities of 2-acetamido-5-O-acetyl-6-O-acyl-2-deoxy-3-O-[(R)-2-propionyl-L-alanyl-D- isoglutamine]-D-glucofuranoses as potential prodrug forms of 6-O-Acyl Derivatives of N-acetylmuramyl dipeptide.
Durette PL; Dorn CP; Friedman A; Schlabach A
J Med Chem; 1982 Sep; 25(9):1028-33. PubMed ID: 7131480
[TBL] [Abstract][Full Text] [Related]
17. Enhancement by murabutide of the immune response to natural and synthetic hepatitis B surface antigens.
Audibert FM; Przewlocki G; Leclerc CD; Jolivet ME; Gras-Masse HS; Tartar AL; Chedid LA
Infect Immun; 1984 Jul; 45(1):261-6. PubMed ID: 6735468
[TBL] [Abstract][Full Text] [Related]
18. Humoral immunoreactivity in chronic active hepatitis: relation to HLA antigens.
Lindberg J; Kaijser B; Lindholm A; Hermodsson S; Iwarson S
Int Arch Allergy Appl Immunol; 1979; 58(1):75-81. PubMed ID: 422281
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the effects of five adjuvants on the antibody response to influenza virus antigen in guinea pigs.
Robuccio JA; Griffith JW; Chroscinski EA; Cross PJ; Light TE; Lang CM
Lab Anim Sci; 1995 Aug; 45(4):420-6. PubMed ID: 7474883
[TBL] [Abstract][Full Text] [Related]
20. Preparation of influenza virosome vaccine with muramyldipeptide derivative B30-MDP.
Ando S; Tsuge H; Mayumi T
J Microencapsul; 1997; 14(1):79-90. PubMed ID: 8994077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
